Calarasi

Researchers are evaluating the immune response and safety of GlaxoSmithKlines investigational chickenpox vaccine and a marketed measles, mumps, and rubella MMR vaccine when given to healthy children aged 12 to 15 months. The study compares these vaccines administered by muscle injection to Mercks chickenpox vaccine given just under the skin. It also assesses the immune response and safety when the GSK vaccines are given together with other routine childhood vaccines. Participants are randomly assigned to receive either the candidate varicella vaccine intramuscularly along with MMR, hepatitis A virus HAV vaccine, and a pneumococcal conjugate vaccine PCV, or the marketed varicella vaccine subcutaneously with the same additional vaccines. The PCV given may be PCV 13, Vaxneuvance, or PCV 20 depending on availability and national recommendations. All vaccines are given on Day 1. Throughout the study, children are monitored for immune responses by measuring antibody levels against varicella zoster virus and MMR antigens at Day 43. Safety is evaluated by tracking any local and systemic reactions in the days following vaccination, as well as any adverse events up to six months after the dose. The study aims to understand both the immune response and safety profile over this period in healthy young children receiving these vaccines.

Researchers are evaluating the effects of switching from combustible cigarettes to a Tobacco Heating System THS in adults with COPD and chronic bronchitis. This randomized study aims to show clinical benefits in symptoms such as cough frequency and shortness of breath, as well as lung function and exercise ability measured by a six-minute walk test. The study focuses on how patients feel and function when switching to THS compared to continuing cigarette smoking. Participants are randomly assigned to either continue smoking cigarettes or switch to using the THS freely without flavor restrictions. The study lasts for 24 weeks, during which the participants use their assigned product as they wish. Researchers compare changes in symptoms, lung function, cough severity, and exposure to harmful substances between the two groups over this period. Throughout the 24 weeks, participants undergo various assessments including cough frequency monitoring, lung function tests, quality of life questionnaires related to cough, and measurements of nicotine and carbon monoxide exposure. These evaluations occur at multiple time points such as weeks 1, 4, 12, and 24. The study tracks symptom changes, respiratory function, and overall health status while ensuring safety monitoring and adherence, providing a comprehensive view of the effects of switching products for people with COPD.